Findings of Research Misconduct, 47699 [2013-18979]

Download as PDF Federal Register / Vol. 78, No. 151 / Tuesday, August 6, 2013 / Notices Dated: August 1, 2013. James R. Park, Executive Director. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2013–18987 Filed 8–5–13; 8:45 am] Office of the Secretary BILLING CODE P Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: FEDERAL RESERVE SYSTEM tkelley on DSK3SPTVN1PROD with NOTICES The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 30, 2013. A. Federal Reserve Bank of San Francisco (Gerald C. Tsai, Director, Applications and Enforcement) 101 Market Street, San Francisco, California 94105–1579: 1. People’s Utah Bancorp, American Fork, Utah; to acquire 100 percent of the voting shares of Lewiston Bancorp, and thereby indirectly acquire voting shares of Lewiston State Bank, both in Lewiston, Utah. Board of Governors of the Federal Reserve System, July 31, 2013. Michael J. Lewandowski, Associate Secretary of the Board. [FR Doc. 2013–18857 Filed 8–5–13; 8:45 am] BILLING CODE 6210–01–P VerDate Mar<15>2010 19:47 Aug 05, 2013 Jkt 229001 Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Pratima Karnik, Ph.D., Case Western Reserve University: Based on the admission of the Respondent, ORI found that Dr. Pratima Karnik, Assistant Professor, Department of Dermatology, Case Western Reserve University (CWRU), engaged in research misconduct in research submitted to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), in grant application R01 AR062378. ORI found that the Respondent engaged in research misconduct by plagiarizing significant portions from research grant application R21 AR061881 that she had reviewed for NIAMS, NIH, and inserting that text into her submitted grant application R01 AR062378–01. Respondent also plagiarized significant portions of text from the following scientific articles and one U.S. patent application available on the Internet: • BMC Med Genomics 4:8, 2011 • J Am Col. Cardiol 52:117–123, 2008 • Nature 457:910–914, 2009 • J Autoimmun 29:310–318, 2007 • U.S. Patent Application No. 20090047269 (published Feb. 19, 2009) • Toxicol Pathol 35:952–957, 2007 • BMC Med Genomics 1:10, 2008 • Open Systems Biology Journal 1:1– 8, 2008 • Endocrinology 146:4189–4191, 2005. • Dr. Karnik has entered into a Voluntary Settlement Agreement and has voluntarily agreed for a period of two (2) years, beginning on July 22, 2013: (1) To have her research supervised; Respondent agreed that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which her participation is proposed and prior to her participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of her duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific SUMMARY: Formations of, Acquisitions by, and Mergers of Bank Holding Companies PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 47699 integrity of her research contribution; she agreed that she shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) That any institution employing her shall submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHSsupported research in which Respondent is involved, a certification to ORI that the content is free of plagiarized material, data provided by Respondent are based on actual experiments or are otherwise legitimately derived, and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and (3) To exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200. David E. Wright, Director, Office of Research Integrity. [FR Doc. 2013–18979 Filed 8–5–13; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30 Day-13–13IF] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call (404) 639–7570 or send an email to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written comments should be received within 30 days of this notice. Proposed Project Pilot Project to Evaluate the Use of Exposure Control Plans for Bloodborne Pathogens in Private Dental Practices –New- National Institute for E:\FR\FM\06AUN1.SGM 06AUN1

Agencies

[Federal Register Volume 78, Number 151 (Tuesday, August 6, 2013)]
[Notices]
[Page 47699]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-18979]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Pratima Karnik, Ph.D., Case Western Reserve University: Based on 
the admission of the Respondent, ORI found that Dr. Pratima Karnik, 
Assistant Professor, Department of Dermatology, Case Western Reserve 
University (CWRU), engaged in research misconduct in research submitted 
to the National Institute of Arthritis and Musculoskeletal and Skin 
Diseases (NIAMS), National Institutes of Health (NIH), in grant 
application R01 AR062378.
    ORI found that the Respondent engaged in research misconduct by 
plagiarizing significant portions from research grant application R21 
AR061881 that she had reviewed for NIAMS, NIH, and inserting that text 
into her submitted grant application R01 AR062378-01. Respondent also 
plagiarized significant portions of text from the following scientific 
articles and one U.S. patent application available on the Internet:
     BMC Med Genomics 4:8, 2011
     J Am Col. Cardiol 52:117-123, 2008
     Nature 457:910-914, 2009
     J Autoimmun 29:310-318, 2007
     U.S. Patent Application No. 20090047269 (published Feb. 
19, 2009)
     Toxicol Pathol 35:952-957, 2007
     BMC Med Genomics 1:10, 2008
     Open Systems Biology Journal 1:1-8, 2008
     Endocrinology 146:4189-4191, 2005.
    
    Dr. Karnik has entered into a Voluntary Settlement Agreement and 
has voluntarily agreed for a period of two (2) years, beginning on July 
22, 2013:
    (1) To have her research supervised; Respondent agreed that prior 
to the submission of an application for U.S. Public Health Service 
(PHS) support for a research project on which her participation is 
proposed and prior to her participation in any capacity on PHS-
supported research, Respondent shall ensure that a plan for supervision 
of her duties is submitted to ORI for approval; the supervision plan 
must be designed to ensure the scientific integrity of her research 
contribution; she agreed that she shall not participate in any PHS-
supported research until such a supervision plan is submitted to and 
approved by ORI; Respondent agreed to maintain responsibility for 
compliance with the agreed upon supervision plan;
    (2) That any institution employing her shall submit in conjunction 
with each application for PHS funds, or report, manuscript, or abstract 
involving PHS-supported research in which Respondent is involved, a 
certification to ORI that the content is free of plagiarized material, 
data provided by Respondent are based on actual experiments or are 
otherwise legitimately derived, and that the data, procedures, and 
methodology are accurately reported in the application, report, 
manuscript, or abstract; and
    (3) To exclude herself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant.

FOR FURTHER INFORMATION CONTACT: Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2013-18979 Filed 8-5-13; 8:45 am]
BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.